\n\n
Recent weeks have seen a flurry of high‑profile developments that signal rapid growth for medical robots. Neptune Medical secured FDA clearance for its Triton 1 robotic endoscopy platform, expanding robot‑assisted procedures into gastrointestinal diagnostics. At the same time, BD introduced a next‑generation pharmacy robot at Fairview, promising faster, more accurate medication dispensing and reduced staffing pressures. In the arena of neurovascular care, XCath’s Iris Surgical System earned an FDA Breakthrough Device designation, clearing a path for remote stroke interventions that could dramatically shrink treatment times. Complementing these regulatory wins, Cornerstone Robotics announced a $700 million partnership with Medtronic, aimed at scaling robotic surgery access worldwide. Together, these approvals and collaborations illustrate why medical robotics are moving from niche tools to mainstream clinical assets, and they set the stage for further innovations in autonomous surgery, tele‑operated interventions, and AI‑enhanced robotic workflows. [[1]]